SAM 101

Drug Profile

SAM 101

Alternative Names: Antipsychotics/minocycline; Minocycline/antipsychotics; SAM-101

Latest Information Update: 05 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MinoGuard
  • Class Antipsychotics; Neuropsychotherapeutics; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Schizophrenia

Highest Development Phases

  • Suspended Schizophrenia

Most Recent Events

  • 31 Jan 2014 Phase II development is ongoing in Israel, UK and Japan
  • 30 Nov 2011 MinoGuard has been acquired by XTL Biopharmaceuticals
  • 25 Mar 2011 XTL Biopharmaceuticals agrees to acquire MinoGuard
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top